Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Could Forest's DDMAC Letter For Off-Label Promotion Doom CEO Solomon?

This article was originally published in The Pink Sheet Daily

Executive Summary

A physician complained to FDA's "Bad Ad" program about a Forest Laboratories sales representative's off-label claims for the fibromyalgia drug Savella.

You may also be interested in...

Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments

The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.

Sunovion Sales Rep Draws FDA Promotional Letter For Declaring Broader Latuda Label Inevitable

While admitting that Sunovion Pharmaceuticals Inc.’s schizophrenia drug Latuda (lurasidone) does not yet have an indication for bipolar I disorder, a sales rep told a psychiatrist it could still be used to treat that condition, FDA’s Office of Prescription Drug Promotion says in a “notice of violation” letter.

"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One

In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts